缩短阿尔茨海默病评估尺度的认知子尺度
Stephen Z Levine1, Yair Goldberg2, Anat Rotstein3
1School of Public Health, University of Haifa, Haifa, Israel.
概括
一个缩短的阿尔茨海默病评估尺度-认知子尺度 (ADAS-Cog) 有效地区分临床试验中的治疗效果. 这种经过验证的七项版本对评估阿尔茨海默氏症进展和治疗疗效有很大的希望.
科学领域:
- 神经科学是一个神经科学.
- 临床心理学 临床心理学
- 心理测量 心理测量 心理测量
背景情况:
- 阿尔茨海默病的临床试验需要可靠的认知测量来区分治疗效果和安慰剂.
- 原始的阿尔茨海默氏病评估尺度-认知子尺度 (ADAS-Cog) 很长,因此需要更短,经过验证的版本进行疗效评估.
研究的目的:
- 开发和验证ADAS-Cog的缩短版本,用于阿尔茨海默病治疗试验.
- 评估缩短的ADAS-Cog在区分多尼佩西尔治疗和安慰剂组之间的有效性.
主要方法:
- 来自五个多尼佩西尔与安慰剂临床试验的参与者数据 (N=2,198) 的二次分析.
- 使用物件响应理论 (IRT) 来识别和开发一个由七个物件组成的ADAS-Cog简体版本.
- 用于重复测量的混合效应模型来比较原始和简短的ADAS-Cog版本之间的效应大小.
主要成果:
- 使用IRT开发了一个由七个项目组成的ADAS-Cog简体版本,有两个响应选项.
- 简短的ADAS-Cog在基线和随访时与原始版本显示出强烈的相关性 (r=0.7).
- 原始和简短的ADAS-Cog版本都与安慰剂相比分离了多尼佩西尔,效果大小分别为0.33和0.25.
结论:
- 来自IRT的简短ADAS-Cog是区分阿尔茨海默病治疗效应的可行的措施.
- 这种缩短的认知尺度具有重要的临床潜力,用于患者评估和监测治疗反应.
相关概念视频
01:26Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
01:30Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113
01:22Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189